Poseida Therapeutics (NASDAQ:PSTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Poseida Therapeutics Stock Performance

Shares of PSTX opened at $3.95 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.56 and a quick ratio of 2.56. The firm has a 50 day moving average of $2.98 and a 200 day moving average of $3.05. Poseida Therapeutics has a twelve month low of $1.60 and a twelve month high of $4.27.

Poseida Therapeutics (NASDAQ:PSTX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.18. The company had revenue of $28.14 million during the quarter, compared to the consensus estimate of $11.25 million. Poseida Therapeutics had a negative net margin of 131.95% and a negative return on equity of 97.36%. Analysts predict that Poseida Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Poseida Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in Poseida Therapeutics by 110.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after purchasing an additional 5,606 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in Poseida Therapeutics in the first quarter worth approximately $33,000. Dynamic Technology Lab Private Ltd purchased a new stake in Poseida Therapeutics in the fourth quarter worth approximately $36,000. Lazard Asset Management LLC boosted its holdings in Poseida Therapeutics by 280.3% in the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after purchasing an additional 21,138 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in Poseida Therapeutics in the fourth quarter worth approximately $76,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.